Please login to the form below

Not currently logged in
Email:
Password:

vedolizumab

This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Professor Carole Longson, director of NICE's health technology evaluation centre, said: Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when compared

Latest news

  • EC approves drugs for diabetes and Crohn’s disease EC approves drugs for diabetes and Crohn’s disease

    The European Commission ( EC) has approved Takeda's Entyvio ( vedolizumab) to treat adults with ulcerative colitis and Crohn's disease and Boehringer Ingelheim/Lilly's Jardiance ( empagliflozin), which adds to the growing list of treatments

  • FDA clears Takeda's <b>vedolizumab</b> for inflammatory bowel disease FDA clears Takeda's vedolizumab for inflammatory bowel disease

    FDA clears Takeda's vedolizumab for inflammatory bowel disease. Entyvio licensed for patients who have not responded to current therapies. ... The FDA approved Entyvio ( vedolizumab) to treat adults with moderate to severe ulcerative colitis ( UC) and

  • FDA panel backs Takeda's inflammatory bowel disease drug FDA panel backs Takeda's inflammatory bowel disease drug

    FDA panel backs Takeda's inflammatory bowel disease drug. Vedolizumab on course for US approval to treat Crohn's disease and ulcerative colitis. ... Takeda's Millennium Pharmaceuticals unit took a step closer to US approval for one of its top pipeline

  • FDA grants priority review to Takeda's colitis drug FDA grants priority review to Takeda's colitis drug

    FDA grants priority review to Takeda's colitis drug. Accelerates review time for vedolizumab. ... One of Takeda's top pipeline prospects - vedolizumab for ulcerative colitis ( UC) - has been given a priority review by the US Food and Drug Administration (

  • Phase III data raise hopes for Takeda's <b>vedolizumab</b> Phase III data raise hopes for Takeda's vedolizumab

    Phase III data raise hopes for Takeda's vedolizumab. Bowel disease drug shows efficacy in ulcerative colitis and Crohn's disease. ... Data from phase III trials of Takeda's inflammatory bowel disease ( IBD) drug vedolizumab suggests the company's

More from news
Approximately 7 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel ( TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel ( TAK-700),

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....